Prescribing GLP-1s for Weight Loss: Patient Selection to Long-Term Care

In this episode of MD Newsline, Dr. Wanda Averhart a general pediatrician and obesity medicine specialist based in Chicago, shares practical insights into the rapidly evolving role of GLP-1 receptor agonists in primary care. Drawing from real-world clinical experience, she explores how these medications are transforming obesity management, patient outcomes, and long-term chronic disease care. Dr. Averhart breaks down the physiology of GLP-1s, explains how they impact appetite, metabolism, and insulin regulation, and discusses their growing role beyond diabetes treatment. She also provides a candid look at patient selection, titration strategies, side effect management, and the importance of setting realistic expectations for long-term therapy. From navigating insurance barriers to addressing social media-driven demand, this episode offers clinicians a grounded, practical framework for integrating GLP-1 therapies into everyday practice while maintaining patient safety and effectiveness. Episode Highlights: Understanding How GLP-1 Medications Work Dr. Averhart explains the three primary mechanisms of GLP-1 receptor agonists—enhancing insulin secretion, slowing gastric emptying, and reducing appetite through brain signaling—creating a powerful combined effect on weight and metabolic health. The Rising Demand for GLP-1s in Clinical Practice Over the past few years, interest in GLP-1 therapies has surged dramatically, driven by both clinical success and widespread public awareness, making obesity management a central focus in primary care. Patient Selection: Indications, Red Flags, and Individualization Appropriate prescribing begins with FDA-approved indications such as obesity, diabetes, or sleep apnea. Dr. Averhart emphasizes the importance of evaluating each patient holistically, including medical history, risks, and readiness for treatment. Titration Strategies and Real-World Flexibility While standard titration protocols exist, treatment is often individualized. Some patients remain on lower doses successfully, while others require escalation, highlighting the importance of patient-centered decision-making. Managing Common and Serious Side Effects Gastrointestinal symptoms like nausea and constipation are common early on and can often be managed with diet, hydration, and dose adjustments. Rare but serious risks such as pancreatitis and thyroid cancer require careful screening and monitoring. Monitoring Progress and Defining Treatment Success Dr. Averhart outlines key lab markers—including A1C, kidney function, thyroid levels, and cholesterol—and defines treatment success as achieving 5–10% weight loss within a few months at therapeutic doses. Long-Term Therapy and Weight Regain Realities GLP-1 medications are framed as long-term or lifelong treatments due to obesity being a chronic condition. Discontinuation often leads to rapid weight regain, making patient education and expectation-setting critical. Behavioral Health Considerations and Eating Disorders Screening for eating disorders is essential before initiating therapy. While some patients report reduced binge tendencies, GLP-1s are not a treatment for eating disorders and should be used cautiously in these populations. Access, Cost, and Insurance Challenges Coverage and prior authorizations heavily influence prescribing decisions. Clinicians must often adapt treatment plans based on what medications are accessible to patients. Future of GLP-1s and Emerging Therapies With new drugs and expanded indications on the horizon, GLP-1 therapies are poised to become standard care across multiple chronic conditions, reshaping the future of primary care medicine. Key Takeaway: Dr. Averhart emphasizes that GLP-1 medications are powerful tools for managing obesity and metabolic disease, but their success depends on careful patient selection, ongoing monitoring, lifestyle integration, and a clear understanding that these therapies are part of long-term chronic disease management.  Resources: Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Wanda Averhart: Here